Daiichi Sankyo   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Shirley NY United States (1947)

Organization Overview

First Clinical Trial
1994
NCT00211705
First Marketed Drug
2000
cevimeline hydrochloride (evoxac)
First NDA Approval
2015
edoxaban (savaysa)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Daichii Sankyo | DAIICHI SANKYO | Daiichi Sankyo Brasil FarmacĂȘutica LTDA | Daiichi Sankyo Co., Ltd. | Daiichi Sankyo Company, Limited | Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo | Daiichi Sankyo Development | Daiichi Sankyo Europe, GmbH | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Daiichi Sankyo Inc. | Daiichi Sankyo, Inc. | DAIICHI SANKYO INC | Daiichi Sankyo Korea Co., Ltd. | Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company | Daiichi Sankyo Taiwan Ltd. | Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company | Daiichi Sankyo UK Ltd. | Luitpold Pharmaceuticals | R&D Division, Daiichi Sankyo Co., Ltd. | Sankyo Shanghai Pharmaceuticals